Null Clobazam Associations in a Small CBD Series Did Not Exclude Drug Interactions
The adult CBD epilepsy series found no statistically significant association between concomitant clobazam and either responder status or drowsiness. Those null comparisons did not establish that clinically relevant interactions were absent.
The study tested two distinct associations
Among 37 patients, the reported clobazam comparison was nonsignificant for achieving at least 50% seizure reduction and for drowsiness. These were observational associations within a selected cohort, rather than randomized comparisons holding other medicines and exposures constant.
A nonsignificant result does not prove equivalence
With a small sample and limited events, a study may not distinguish meaningful differences precisely. The reported p-values do not demonstrate that the groups had identical effects. They also do not measure the pharmacokinetic interaction directly; the paper did not use these comparisons to establish unchanged drug concentrations.
Retain the clinical context
Concomitant antiseizure regimens changed during follow-up, and tolerability may have affected achieved CBD dosing. These factors complicate attribution. A balanced summary preserves the null findings without presenting them as a guarantee that combining the medicines has no consequences. The series contributes practical observations that can guide further research, while leaving a controlled interaction estimate and individual treatment decisions outside what those comparisons establish.
Related analysis: the source’s broader findings and limitations.
